Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2023 · 1 min read
In brief
In brief
This phase 3 randomized controlled trial demonstrates that nirogacestat, an oral γ-secretase inhibitor, significantly improves progression-free survival in adults with progressing desmoid tumors compared to placebo (76% vs 44% event-free at 2 years). The drug also achieved higher objective response rates (41% vs 8%) and improved patient-reported outcomes including pain and physical functioning.
Written by the GCMD Library team from the article.
Statements in this article
Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.
Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat at 150 mg or placebo twice daily.
Nirogacestat had a significant progression-free survival benefit over placebo with a hazard ratio for disease progression or death of 0.29 (95% confidence interval, 0.15 to 0.55; P<0.001).
The likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo.
The percentage of patients who had an objective response was significantly higher with nirogacestat than with placebo (41% vs. 8%; P<0.001).
The median time to response was 5.6 months with nirogacestat and 11.1 months with placebo.
The percentage of patients with a complete response was 7% with nirogacestat and 0% with placebo.
Significant between-group differences were observed in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life.